Assessment of different antibacterial effect measures used in in vitro models of infection and subsequent use in pharmacodynamic correlations for moxifloxacin

Journal of Antimicrobial Chemotherapy

Volumn 46, Issue 1, 2000, Pages 73-78

  MacGowan, Alasdair ^a   Rogers, Chris ^a   Holt, H Alan ^a   Wootton, Mandy ^a   Bowker, Karen ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; BETA HEMOLYTIC STREPTOCOCCUS; CONTROLLED STUDY; DRUG EFFECT; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONBIOLOGICAL MODEL; NONHUMAN; PARAMETER; PHARMACODYNAMICS; SIMULATION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; ANIMAL; BACTERIUM; MICROBIOLOGICAL EXAMINATION;

ANIMALS; ANTI-INFECTIVE AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; BACTERIA; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; QUINOLINES;

EID: 0033910791     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/46.1.73     Document Type: Article

References (22)

1. Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C. & Schentag, J. J. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37, 1073-81.
2. Forrest, A., Chodosh, S., Amantea, M. A., Collins, D. A. & Schentag, J. J. (1997). Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 45-57.
3. Preston, S. L., Drusano, G. L., Berman, A. L., Fowler, C. L., Chow, A. T., Dornsief, B. et al. (1998). Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. Journal of the American Medical Association 279, 125-9.
4. Thomas, J. K., Forrest, A., Bhavnani, S. M., Hyatt, J. M., Cheng, A., Ballow, C. G. et al. (1998). Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrobial Agents and Chemotherapy 42, 521-7.
5. Firsov, A. A., Vostrov, S. N., Shevchenko, A. A. & Cornaglia, G. (1997). Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model. Antimicrobial Agents and Chemotherapy 41, 1281-7.
6. Rustige, C. & Wiedmann, B. (1990). Antibacterial activity of lomefloxacin in a pharmacokinetic in vitro model. Antimicrobial Agents and Chemotherapy 34, 1107-11.
7. Bowker, K. E., Holt, H. A., Lewis, R. J., Reeves, D. S. & MacGowan, A. P. (1998). Comparative pharmacodynamics of meropenem using an in-vitro model to simulate once, twice and three times daily dosing in humans. Journal of Antimicrobial Chemotherapy 42, 461-7.
8. Madaras-Kelly, K. J., Ostergaard, B. E., Horde, L. B. & Rotschafer, J. C. (1996). Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model. Antimicrobial Agents and Chemotherapy 40, 627-32.
9. Aeschlimann, J. R., Hershberger, E. & Rybak, M. J. (1998). Pharmacodynamic predictors of activity for ampicillin/sulbactam and trovafloxacin versus vancomycin intermediate Staphylococcus aureus in an in vitro model. In Program and Abstracts of the Thirty-Eighth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, 1998. Abstract A-38, American Society for Microbiology, Washington, DC.
10. Blaser, J., Stone, B. B., Groner, M. C. & Zinner, S. H. (1987). Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrobial Agents and Chemotherapy 31, 1054-60.
11. Bauernfeind, A. (1993). Questioning dosing regimens of ciprofloxacin. Journal of Antimicrobial Chemotherapy 31, 789-98.
12. Kang, S. L., Ryback, M. J., McGrath, B. J., Kaatz, G. W. & Seo, S. M. (1994). Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model. Antimicrobial Agents and Chemotherapy 38, 2702-9.
13. Bowker, K. E., Rogers, C., Wootton, M. & MacGowan, A. P. (1998). The use of different pharmacodynamic parameters and descriptors of antibacterial effect in comparing once and twice a day dosing with ciprofloxacin. In Abstracts of the Eighth International Congress on Infectious Diseases, Boston, MA, 1998, 12.022, 17. International Society for Infectious Diseases.
14. Hoang, A. D., Peterson, L., Horde, L. B., Wright, D. & Rotschafer, J. C. (1998). Investigation of AUC/MIC ratio as a generic predictor of fluoroquinolone activity against Staphylococcus aureus using trovafloxacin, clinafloxacin, ciprofloxacin, sparfloxacin, levofloxacin and an in vitro model. Abstract of the Ninety-Eighth General Meeting, American Society for Microbiology, Atlanta, GA. A71, p. 50. American Society for Microbiology, Washington, DC.
15. Wright, D. H., Hovde, L. B., Peterson, M. L., Hoang, A. D. & Rotschafer, J. C. (1998). In vitro evaluation of pharmacodynamic outcome parameters for three fluoroquinolones against Streptococcus pneumoniae. Abstracts of the Ninety-Eighth General Meeting, American Society for Microbiology, Atlanta, GA. A86, p. 53. American Society for Microbiology, Washington, DC.
16. MacGowan, A. P., Bowker, K. E., Wootton, M. & Holt, H. A. (1999). Activity of moxifloxacin administered once a day against Streptococcus pneumoniae in an in vitro pharmacodynamic model of infection. Antimicrobial Agents and Chemotherapy 43, 1560-4.
17. MacGowan, A. P., Bowker, K. E., Wootton, M. & Holt, H. A. (1999). The in vitro activity of moxifloxacin against Haemophilus influenzae and Moraxella catarrhalis explored using a pharmacodynamic model. Clinical Microbiology and Infection 5, 195-200.
18. MacGowan, A. P., Bowker, K. E., Wootton, M. & Holt, H. A. (1999). The in-vitro pharmacodynamic activity of moxifloxacin for Staphylococcus aureus and streptococci of Lancefield groups A and G. Journal of Antimicrobial Chemotherapy 44, 761-6.
19. Firsov, A. A., Shevchenko, A. A., Vostrov, S. N. & Zinner, S. H. (1998). Inter- and intra-quinolone predictors of antimicrobial effect in an in vitro dynamic model: new insight into a widely used concept. Antimicrobial Agents and Chemotherapy 42, 659-65.
20. Palmer, S. M. & Rybak, M. J. (1995). Pharmacodynamics of once or twice daily levofloxacin vs vancomycin +/- rifampicin against Staphylococcus aureus in an in vitro model with simulated vegetations. In Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995, A66. American Society for Microbiology, Washington, DC.
21. MacGowan, A. P., Wootton, M., Hedges, A. J., Bowker, K. E., Holt, H. A. & Reeves, D. S. (1996). A new time-kill method of assessing the relative efficacy of antimicrobial agents alone and in combination developed using a representative β-lactam, aminoglycoside and fluoroquinolone. Journal of Antimicrobial Chemotherapy 38, 193-203.
22. Vesga, O., Conklin, R., Stamstad, T. & Craig, W. A. (1996). Pharmacodynamic activity of Bay 12-8039 in animal infection models. Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA. Abstract F22, p. 103. American Society for Microbiology, Washington, DC.